On the cusp of a cure for COVID, one of the most promising yet under-the-radar biotech stocks on the OTC is generating much well-deserved buzz in...
Last month, BioXyTran Inc (OTCMKTS: BIXT) achieved a once-in-a-decade type event with their announcement of a perfect phase 2 clinical trial outcome with a 100% response...
One of the most exciting advances in biotechnology is the galectin inhibitor. Galectins are key proteins implicated in a wide range of chronic diseases. The leading...
Galectin Therapeutics (NASDAQ: GALT), Galecto Biotech (NASDAQ: GLTO), and BioXyTran Inc. (OTCMKTS: BIXT)—these three companies all currently have market capitalizations under $100 million in the field...
Bioxytran Inc (OTCMKTS: BIXT) is making some solid move up the charts as the broader markets suffer their worst losses since 2008. The stock which saw...